WHO ICTRP trial
Nivolumab dose optimization in patients with a complete, partial or stable…
CTIS2024-516718-39-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-516718-39-00 |
|---|---|
| Public title | Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial) |
| Scientific title | Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial) |
| Primary sponsor | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): Yes |
| Countries | Netherlands |
| Conditions | Melanoma, Renal cell carcinoma;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: , Product Code:SCP8265340, Pharmaceutical Form: , Other descriptive name: , Strength: |
| Registration date | Jul 30, 2024 |
| Target size | 34 |
| Secondary IDs | NCT06116461;2021-001707-32 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: